||Last Updated: Nov 17th, 2006 - 22:35:04
Cystic fibrosis-related diabetes is due to functional abnormalities in beta cells
A growing number of cystic fibrosis patients are battling a second, often deadly complication: a unique form of diabetes that shares characteristics of the type 1 and type 2 versions that strike many Americans. Many of these patients are teens who take enzymes to help digest their food and undergo daily physical therapy to loosen the thick, sticky mucus that clogs their lungs. But despite treatments that are helping thousands to live decades longer than ever before, when diabetes strikes, their life expectancy plummets -- on average by two years for men and an astounding 16 for women.
Jul 10, 2006, 06:21
No evidence for inhaled corticosteroids efficacy in cystic fibrosis
In comparison to cystic fibrosis (CF) patients who regularly use inhaled corticosteroid, those who did not use these drugs for six months exhibited no positive or negative effects in terms of major disease factors. Such factors include amount of lung function decline, number of antibiotics prescribed, time to onset of acute chest exacerbation or frequency of using a bronchodilator.
Jun 15, 2006, 16:57
Hcp1 plays a critical role in cystic fibrosis infection
Harvard Medical School researchers have discovered one way that a hardy disease-causing bacteria could be surviving in the lungs of chronically infected cystic fibrosis (CF) patients. This work is important because pathogenic bacteria such as Pseudomonas aeruginosa (PA) use protein secretion systems to cause disease in their hosts. In the case of Pseudomonas aeruginosa, the host may be a cancer patient with a weakened immune system, a burn patient, or a person with cystic fibrosis (CF). Pseudomonas aeruginosa (PA), a pathogen that infects more than 80 percent of cystic fibrosis patients, is a leading cause of these patients' death. PA is difficult to treat because it is resistant to many drugs.
Jun 10, 2006, 13:43
Cystic fibrosis research could benefit from multi-functional sensing tool
Researchers are using an innovative, multi-functional sensing tool to investigate adenosine triposphate (ATP) release and its role in cystic fibrosis. The ATP study marks the first application of a novel sensing system developed by a research team led by Christine Kranz at the Georgia Institute of Technology.
Mar 27, 2006, 16:17
Loss of CFTR-mediated fluid secretion is the culprit in cystic fibrosis
Scientists at Stanford University have determined that the buildup of sticky mucus found in cystic fibrosis is caused by a loss in the epithelial cell's ability to secrete fluid. This research appears as the "Paper of the Week" in the March 17 issue of the Journal of Biological Chemistry, an American Society for Biochemistry and Molecular Biology journal.
Mar 19, 2006, 20:56
New treatment for cystic fibrosis patients
Scientists have discovered a new therapy for lung problems associated with cystic fibrosis that they say may reduce the use of antibiotics.
Jan 19, 2006, 13:10
Genetic variations influence cystic fibrosis' severity
Subtle differences in other genes -- besides the defective gene known to cause the illness cystic fibrosis -- can significantly modify the inherited disease's severity, a large new multi-center national study has concluded. The study, led by University of North Carolina at Chapel Hill and Case Western Reserve University researchers, for the first time shows that particular versions of the transforming growth factor beta 1 (TGFb1) gene are largely responsible for how badly the illness affects patients' lungs.
Oct 8, 2005, 05:24
How to design a better drug to treat cystic fibrosis
There is no cure for cystic fibrosis. Management of the disease varies from person to person and generally focuses on treating respiratory and digestive problems to prevent infection and other complications. Treatment usually involves a combination of medications and home treatment methods, such as respiratory and nutritional therapies.
Sep 4, 2005, 08:30
FDA Gives Clearance to the First Cystic Fibrosis DNA test
Tm Bioscience Corporation (Toronto, Ontario; TSX: TMC), a leader in the commercial genetic testing market, is pleased to announce that its Tag-It(TM) Cystic Fibrosis (CF) Kit is the first multiplexed human disease genotyping test to be cleared by the U.S. Food and Drug Administration (FDA) as an in vitro device (IVD) for diagnostic use in the United States.
May 10, 2005, 09:18